share_log

HC Wainwright & Co. Upgrades Akebia Therapeutics to Buy, Raises Price Target to $3.75

Benzinga ·  Aug 28, 2023 06:30

HC Wainwright & Co. analyst Ed Arce upgrades Akebia Therapeutics (NASDAQ:AKBA) from Neutral to Buy and raises the price target from $2 to $3.75.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment